Flow cytometry has gone through many changes in the past decades, and it continues to gain greater utility in drug development testing for pharmaceutical and biotechnology companies. The usage of flow cytometry has had recent advances in complexity, including flow cytometry instrument designs, reagents, and analysis algorithms.

Mark Edinger, scientific affairs director of flow cytometry, was interviewed by Applied Clinical Trials, where he discussed trends in next generation flow cytometry. Read the article to learn how flow cytometry has become a central part of the development of new immunotherapies, and how next generation flow cytometry will become an even more essential tool in discovery as it continues to expand its capability and utility.